TScan Therapeutics (TCRX) EBT Margin (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly EBT Margin of 2919.14% for Q1 2026, down 121560.0% year-over-year from N/an in Q1 2025, and down 135.32% quarter-over-quarter from 1240.51% in Q4 2025.
TScan Therapeutics (TCRX) EBT Margin (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported EBT Margin for 7 consecutive years, with 2919.14% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin fell 121560.0% year-over-year to 2919.14%; the TTM figure through Mar 2026 stood at 1457.66% (up 182813.0% YoY), while the FY2025 annual figure was 2129.37%, up 300451.0% from the prior year.
- EBT Margin fell to 2919.14% in Q1 2026 per TCRX's latest filing, from 1240.51% in the prior quarter.
- Across five years, EBT Margin topped out at 280.95% in Q4 2023 and bottomed at 7027.52% in Q4 2024.
- Historically, EBT Margin has averaged 1978.98% across 5 years, with a median of 1201.3% in 2025.
- Annual changes were most pronounced in 2024 — EBT Margin slumped 674657 bps — and 2025, when it soared 578700 bps.
- TScan Therapeutics' EBT Margin stood at 631.57% in 2022, then surged by 56 bps to 280.95% in 2023, then plunged by 2401 bps to 7027.52% in 2024, then soared by 82 bps to 1240.51% in 2025, then slumped by 135 bps to 2919.14% in 2026.
- Business Quant data shows TCRX's EBT Margin at 2919.14% in Q1 2026, 1240.51% in Q4 2025, and 1422.14% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | TScan Therapeutics | 101.63 Mn | 101.63 Mn | - | -2,888.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,888.58% |
| Mar 31, 2026 | -2,919.14% |
| Dec 31, 2025 | -1,240.51% |
| Sep 30, 2025 | -1,422.14% |
| Jun 30, 2025 | -1,201.30% |
| Mar 31, 2025 | -1,703.55% |
| Dec 31, 2024 | -7,027.52% |
| Sep 30, 2024 | -2,849.09% |
| Jun 30, 2024 | -5,906.90% |
| Mar 31, 2024 | -5,325.44% |
| Dec 31, 2023 | -280.95% |
| Sep 30, 2023 | -591.64% |
| Jun 30, 2023 | -763.82% |
| Mar 31, 2023 | -389.02% |
| Dec 31, 2022 | -631.57% |
| Sep 30, 2022 | -483.05% |
| Jun 30, 2022 | -372.21% |
| Mar 31, 2022 | -534.79% |
| Dec 31, 2021 | -521.65% |
| Sep 30, 2021 | -1,048.55% |